1. Home
  2. ZYME vs MLKN Comparison

ZYME vs MLKN Comparison

Compare ZYME & MLKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • MLKN
  • Stock Information
  • Founded
  • ZYME 2003
  • MLKN 1905
  • Country
  • ZYME United States
  • MLKN United States
  • Employees
  • ZYME N/A
  • MLKN N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • MLKN Office Equipment/Supplies/Services
  • Sector
  • ZYME Health Care
  • MLKN Consumer Discretionary
  • Exchange
  • ZYME Nasdaq
  • MLKN Nasdaq
  • Market Cap
  • ZYME 1.2B
  • MLKN 1.1B
  • IPO Year
  • ZYME 2017
  • MLKN N/A
  • Fundamental
  • Price
  • ZYME $18.08
  • MLKN $17.08
  • Analyst Decision
  • ZYME Strong Buy
  • MLKN
  • Analyst Count
  • ZYME 8
  • MLKN 0
  • Target Price
  • ZYME $24.00
  • MLKN N/A
  • AVG Volume (30 Days)
  • ZYME 668.9K
  • MLKN 677.7K
  • Earning Date
  • ZYME 11-06-2025
  • MLKN 09-23-2025
  • Dividend Yield
  • ZYME N/A
  • MLKN 4.51%
  • EPS Growth
  • ZYME N/A
  • MLKN N/A
  • EPS
  • ZYME N/A
  • MLKN N/A
  • Revenue
  • ZYME $122,867,000.00
  • MLKN $3,764,100,000.00
  • Revenue This Year
  • ZYME $107.76
  • MLKN $5.37
  • Revenue Next Year
  • ZYME $2.35
  • MLKN $3.67
  • P/E Ratio
  • ZYME N/A
  • MLKN N/A
  • Revenue Growth
  • ZYME 95.94
  • MLKN 5.37
  • 52 Week Low
  • ZYME $9.03
  • MLKN $15.25
  • 52 Week High
  • ZYME $19.50
  • MLKN $25.96
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 65.50
  • MLKN 40.74
  • Support Level
  • ZYME $18.21
  • MLKN $16.50
  • Resistance Level
  • ZYME $19.10
  • MLKN $17.10
  • Average True Range (ATR)
  • ZYME 0.69
  • MLKN 0.45
  • MACD
  • ZYME 0.02
  • MLKN 0.12
  • Stochastic Oscillator
  • ZYME 56.97
  • MLKN 50.32

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About MLKN MillerKnoll Inc.

MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.

Share on Social Networks: